BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors

Multiple tumor types overexpress Nectin-4 and the antibody–drug conjugate (ADC), enfortumab vedotin (EV) shows striking efficacy in clinical trials for metastatic urothelial cancer, which expresses high levels of Nectin-4, validating Nectin-4 as a clinical target for toxin delivery in this indicatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Rigby, Michael, Bennett, Gavin, Chen, Liuhong, Mudd, Gemma E., Harrison, Helen, Beswick, Paul J., Van Rietschoten, Katerine, Watcham, Sophie M., Scott, Heather S., Brown, Amy N., Park, Peter U., Campbell, Carly, Haines, Eric, Lahdenranta, Johanna, Skynner, Michael J., Jeffrey, Phil, Keen, Nicholas, Lee, Kevin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
MCT First Disclosures
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9940631/
https://www.ncbi.nlm.nih.gov/pubmed/36112771
http://dx.doi.org/10.1158/1535-7163.MCT-21-0875

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9940631/
https://www.ncbi.nlm.nih.gov/pubmed/36112771
http://dx.doi.org/10.1158/1535-7163.MCT-21-0875

Ejemplares similares